e-learning
resources
Berlin 2008
Monday, 06.10.2008
Improving asthma and anti-allergic therapy
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Safety and immunogenicity of hemophilus influenzae type B conjugate vaccine in COPD
N. S. Reddy, M. Khan, N. Methuku, S. Bodi, Aleem (Hyderabad, India)
Source:
Annual Congress 2008 - Improving asthma and anti-allergic therapy
Session:
Improving asthma and anti-allergic therapy
Session type:
Thematic Poster Session
Number:
2017
Disease area:
Airway diseases, Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
N. S. Reddy, M. Khan, N. Methuku, S. Bodi, Aleem (Hyderabad, India). Safety and immunogenicity of hemophilus influenzae type B conjugate vaccine in COPD. Eur Respir J 2008; 32: Suppl. 52, 2017
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Respiratory sequelae of preterm birth across the life span
Related content which might interest you:
Late Breaking Abstract - Safety and immunogenicity of non-typeable H. influenzae (NTHi) and M. catarrhalis (Mcat) adjuvanted vaccines in adults
Source: International Congress 2018 – COPD exacerbations and bronchiectasis
Year: 2018
Late Breaking Abstract - Safety and immunogenicity of non-typeable H. influenzae (NTHi) adjuvanted vaccine in older adults with chronic obstructive pulmonary disease (COPD)
Source: International Congress 2018 – COPD exacerbations and bronchiectasis
Year: 2018
Clinical impact of a non-typeable Haemophilus influenzae (NTHi) adjuvanted vaccine in adults with chronic obstructive pulmonary disease (COPD)
Source: International Congress 2019 – COPD clinical trials: new molecules and novel insights
Year: 2019
Vaccination of COPD patients with a pneumococcus type 6B tetanus toxoid conjugate vaccine
Source: Eur Respir J 2002; 20: 813-818
Year: 2002
Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia
Source: Eur Respir J 2015; 45: 1632-1641
Year: 2015
Effectiveness of a 23-valent pneumococcal polysaccharide vaccine and a 13-valent pneumococcal conjugate vaccine among the elderly with chronic respiratory diseases
Source: International Congress 2018 – Pneumonia: from the community to the intensive care unit
Year: 2018
Clinical evolution of patients with COPD after administration of 23-valent pneumococcal capsular polysacharide vaccine (PCPV)
Source: Eur Respir J 2005; 26: Suppl. 49, 286s
Year: 2005
Pneumococcal vaccination: current and future issues
Source: Eur Respir J 2001; 18: 184-195
Year: 2001
Effectiveness data on prevention of COPD exacerbations with 13-valent pneumococal conjugate vaccine (PCV13)
Source: International Congress 2017 – Discussion of vaccines, biomarkers and risk factors analysis
Year: 2017
Effectiveness of the pneumococcal polysaccharide vaccine in preventing pneumonia in the elderly
Source: Eur Respir J 2010; 36: 608-614
Year: 2010
Introduction of the 13-valent pneumococcal conjugate vaccine in an isolated pneumococcal vaccine-naïve indigenous population
Source: Eur Respir J 2016; 48: 1492-1496
Year: 2016
Previous pneumococcal polysaccharide vaccine impacts immune response to subsequent pneumococcal conjugate vaccine in the elderly
Source: Eur Respir J 2005; 26: Suppl. 49, 673s
Year: 2005
Use of the pneumococcal 23-valent polysaccharide vaccine in recruits in Russia
Source: Eur Respir J 2004; 24: Suppl. 48, 363s
Year: 2004
Microbiological efficacy of combined use of vaccines against S. pneumoniae, H. influenzae type B in patients with a COPD
Source: Annual Congress 2011 - Role of infection in exacerbations of COPD
Year: 2011
Aetiology of paediatric pneumonia after the introduction of pneumococcal conjugate vaccine
Source: Eur Respir J 2013; 42: 1595-1603
Year: 2013
HI-164, an oral vaccine to non-typable
haemophilus influenzae
, reduces antibiotic use, respiratory exacerbations and hospitalisations in patients with COPD
Source: Annual Congress 2007 - Different aspects of COPD exacerbations
Year: 2007
Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands
Source: Eur Respir J 2015; 46: 1407-1416
Year: 2015
Additive preventive effect of influenza and pneumococcal vaccines in elderly persons
Source: Eur Respir J 2004; 23: 363-368
Year: 2004
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept